Zymeworks Inc. Common Stock (ZYME) - Total Assets
Based on the latest financial reports, Zymeworks Inc. Common Stock (ZYME) holds total assets worth $397.27 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Zymeworks Inc. Common Stock - Total Assets Trend (2014–2024)
This chart illustrates how Zymeworks Inc. Common Stock's total assets have evolved over time, based on quarterly financial data. Also see ZYME market cap for the company's overall valuation and market capitalisation.
Zymeworks Inc. Common Stock - Asset Composition Analysis
Current Asset Composition (December 2024)
Zymeworks Inc. Common Stock's total assets of $397.27 Million consist of 64.9% current assets and 35.1% non-current assets. Review Zymeworks Inc. Common Stock balance sheet liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 14.3% |
| Accounts Receivable | $55.81 Million | 12.1% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $4.58 Million | 1.0% |
| Goodwill | $12.02 Million | 2.6% |
Asset Composition Trend (2014–2024)
This chart illustrates how Zymeworks Inc. Common Stock's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See ZYME stock price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Zymeworks Inc. Common Stock's current assets represent 64.9% of total assets in 2024, a decrease from 98.8% in 2014.
- Cash Position: Cash and equivalents constituted 14.3% of total assets in 2024, down from 92.4% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, an increase from 0.0% in 2014.
- Asset Diversification: The largest asset category is accounts receivable at 12.1% of total assets.
Zymeworks Inc. Common Stock Competitors by Total Assets
Key competitors of Zymeworks Inc. Common Stock based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B
|
Denmark | Dkr9.17 Billion |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM
|
USA | $890.92 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF3.09 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Inhibrx Biosciences, Inc.
NASDAQ:INBX
|
USA | $183.97 Million |
|
Wuhan Keqian Biology Co Ltd
SHG:688526
|
China | CN¥4.75 Billion |
Zymeworks Inc. Common Stock - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 6.94 | 4.10 | 5.31 |
| Quick Ratio | 6.94 | 4.10 | 5.31 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $249.67 Million | $259.86 Million | $369.41 Million |
Zymeworks Inc. Common Stock - Advanced Valuation Insights
This section examines the relationship between Zymeworks Inc. Common Stock's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.57 |
| Latest Market Cap to Assets Ratio | 3.86 |
| Asset Growth Rate (YoY) | -20.3% |
| Total Assets | $463.09 Million |
| Market Capitalization | $1.79 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Zymeworks Inc. Common Stock's assets at a significant premium (3.86x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Zymeworks Inc. Common Stock's assets decreased by 20.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Zymeworks Inc. Common Stock (2014–2024)
The table below shows the annual total assets of Zymeworks Inc. Common Stock from 2014 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $463.09 Million | -20.28% |
| 2023-12-31 | $580.88 Million | -10.46% |
| 2022-12-31 | $648.73 Million | +66.71% |
| 2021-12-31 | $389.13 Million | -27.72% |
| 2020-12-31 | $538.38 Million | +46.22% |
| 2019-12-31 | $368.20 Million | +50.68% |
| 2018-12-31 | $244.36 Million | +85.19% |
| 2017-12-31 | $131.96 Million | +40.39% |
| 2016-12-31 | $94.00 Million | +306.04% |
| 2015-12-31 | $23.15 Million | -54.32% |
| 2014-12-31 | $50.68 Million | -- |
About Zymeworks Inc. Common Stock
Zymeworks Inc., a clinical-stage biotechnology company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer, and autoimmune and inflammatory diseases (AIID). Its therapeutic platforms and fully integrated drug development engine provides the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutic candidates. … Read more